Importantly, in support of a recent report elucidating the beneficial role sustained by the immunodepletion of N-terminal projection of tau (residues 6-18) in improving memory deficits in 3XTgAD mice [20], these results hopefully prospect that passive immunization with the our newly-developed 12A12 monoclonal antibody targeting the N-terminal sequence of human protein encompassing the 26-44 aminoacidic stretch could actually represent an effective therapeutic opportunity for AD and other tauopathies. Here, MAPT is linked to tauopathy.